PDF herunterladen
Semin Neurol 2023; 43(06): 889-896
DOI: 10.1055/s-0043-1776764
Review Article

Neuro-oncology Treatment Strategies for Primary Glial Tumors

Fernando Santos-Pinheiro
1   Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Jerome J. Graber
2   Department of Neurology and Neurosurgery, University of Washington, Alvord Brain Tumor Center, Seattle, Washington
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Primary brain tumors underwent reclassification in the 2021 World Health Organization update, relying on molecular findings (especially isocitrate dehydrogenase mutations and chromosomal changes in 1p, 19q, gain of chromosome 7 and loss of chromosome 10). Newer entities have also been described including histone 3 mutant midline gliomas. These updated pathologic classifications improve prognostication and reliable diagnosis, but may confuse interpretation of prior clinical trials and require reclassification of patients diagnosed in the past. For patients over seventy, multiple studies have now confirmed the utility of shorter courses of radiation, and the risk of post-operative delirium. Ongoing studies are comparing proton to photon radiation. Long term follow up of prior clinical trials have confirmed the roles and length of chemotherapy (mainly temozolomide) in different tumors, as well as the wearable novottf device. New oral isocitrate dehydrogenase inhibitors have also shown efficacy in clinical trials.

Keywords

brain tumor - glioblastoma - astrocytoma - oligodendroglioma - brain cancer


Publikationsverlauf

Artikel online veröffentlicht:
14. Dezember 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ostrom QT, Cioffi G, Gittleman H. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-oncol 2019; 21 (Suppl. 05) v1-v100
    CrossrefPubMedGoogle Scholar
  • 2 Brat DJ, Aldape K, Colman H. et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020; 139 (03) 603-608
    CrossrefPubMedGoogle Scholar
  • 3 Houillier C, Wang X, Kaloshi G. et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75 (17) 1560-1566
    CrossrefPubMedGoogle Scholar
  • 4 Sanson M, Marie Y, Paris S. et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27 (25) 4150-4154
    CrossrefPubMedGoogle Scholar
  • 5 Dang L, White DW, Gross S. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462 (7274): 739-744
    CrossrefPubMedGoogle Scholar
  • 6 Yan H, Parsons DW, Jin G. et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360 (08) 765-773
    CrossrefPubMedGoogle Scholar
  • 7 Lu C, Ward PS, Kapoor GS. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483 (7390): 474-478
    CrossrefPubMedGoogle Scholar
  • 8 Reczek CR, Chandel NS. ROS promotes cancer cell survival through calcium signaling. Cancer Cell 2018; 33 (06) 949-951
    CrossrefPubMedGoogle Scholar
  • 9 Chen H, Judkins J, Thomas C. et al. Mutant IDH1 and seizures in patients with glioma. Neurology 2017; 88 (19) 1805-1813
    CrossrefPubMedGoogle Scholar
  • 10 Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993; 52 (06) 609-618
    CrossrefPubMedGoogle Scholar
  • 11 Pasquier B, Pasquier D, N'Golet A, Panh MH, Couderc P. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer 1980; 45 (01) 112-125
    CrossrefPubMedGoogle Scholar
  • 12 Andersen BM, Miranda C, Hatzoglou V, DeAngelis LM, Miller AM. Leptomeningeal metastases in glioma: the Memorial Sloan Kettering Cancer Center experience. Neurology 2019; 92 (21) e2483-e2491
    CrossrefPubMedGoogle Scholar
  • 13 Zetterling M, Berhane L, Alafuzoff I, Jakola AS, Smits A. Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases. PLoS One 2017; 12 (11) e0188419
    CrossrefPubMedGoogle Scholar
  • 14 Patel SH, Poisson LM, Brat DJ. et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA Project. Clin Cancer Res 2017; 23 (20) 6078-6085
    CrossrefPubMedGoogle Scholar
  • 15 Throckmorton P, Graber JJ. T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: variability and evolution. Neurology 2020; 95 (11) e1582-e1589
    CrossrefPubMedGoogle Scholar
  • 16 Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data. Neuro-oncol 2018; 20 (12) 1573-1583
    CrossrefPubMedGoogle Scholar
  • 17 Smith JS, Chang EF, Lamborn KR. et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008; 26 (08) 1338-1345
    CrossrefPubMedGoogle Scholar
  • 18 Jakola AS, Skjulsvik AJ, Myrmel KS. et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 2017; 28 (08) 1942-1948
    CrossrefPubMedGoogle Scholar
  • 19 Karschnia P, Vogelbaum MA, van den Bent M. et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer 2021; 149: 23-33
    CrossrefPubMedGoogle Scholar
  • 20 Rossi M., Ambrogi F., Gay L., Gallucci M., Conti Nibali M., Leonetti A., Puglisi G., Sciortino T., Howells H., Riva M., Pessina F., Navarria P., Franzese C., Simonelli M., Rudà R., Bello L.. (2020). Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. Journal of Neurosurgery JNS 132 (06) 1692-1705
    CrossrefPubMedGoogle Scholar
  • 21 Pallud J, Varlet P, Devaux B. et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology 2010; 74 (21) 1724-1731
    CrossrefPubMedGoogle Scholar
  • 22 van den Bent MJ, Afra D, de Witte O. et al; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366 (9490): 985-990
    CrossrefPubMedGoogle Scholar
  • 23 Shaw E, Arusell R, Scheithauer B. et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20 (09) 2267-2276
    CrossrefPubMedGoogle Scholar
  • 24 Ali AN, Zhang P, Yung WKA. et al. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 2018; 137 (01) 39-47
    CrossrefPubMedGoogle Scholar
  • 25 Shaw EG, Wang M, Coons SW. et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012; 30 (25) 3065-3070
    CrossrefPubMedGoogle Scholar
  • 26 Buckner JC, Shaw EG, Pugh SL. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016; 374 (14) 1344-1355
    CrossrefPubMedGoogle Scholar
  • 27 van den Bent MJ, Brandes AA, Taphoorn MJ. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31 (03) 344-350
    CrossrefPubMedGoogle Scholar
  • 28 Cairncross G, Wang M, Shaw E. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31 (03) 337-343
    CrossrefPubMedGoogle Scholar
  • 29 Lassman AB, Hoang-Xuan K, Polley MC. et al. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol 2022; 40 (23) 2539-2545
    CrossrefPubMedGoogle Scholar
  • 30 van den Bent MJ, Baumert B, Erridge SC. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017; 390 (10103): 1645-1653
    CrossrefPubMedGoogle Scholar
  • 31 Wick W, Roth P, Hartmann C. et al; Neurooncology Working Group (NOA) of the German Cancer Society. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-oncol 2016; 18 (11) 1529-1537
    PubMedGoogle Scholar
  • 32 Jaeckle KA, Ballman KV, van den Bent M. et al. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-oncol 2021; 23 (03) 457-467
    CrossrefPubMedGoogle Scholar
  • 33 Mohile NA, Messersmith H, Gatson NT. et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO Guideline. J Clin Oncol 2022; 40 (04) 403-426
    CrossrefPubMedGoogle Scholar
  • 34 Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007; 69 (13) 1366-1373
    CrossrefPubMedGoogle Scholar
  • 35 Claus EB, Walsh KM, Wiencke JK. et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015; 38 (01) E6
    CrossrefPubMedGoogle Scholar
  • 36 Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev 2017; 40 (01) 1-14
    CrossrefPubMedGoogle Scholar
  • 37 Mair MJ, Geurts M, van den Bent MJ, Berghoff AS. A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treat Rev 2021; 92: 102124
    CrossrefPubMedGoogle Scholar
  • 38 Dirven L, Taphoorn MJB. Evaluating the lack of impact of the e-health application Oncokompas on outcomes in incurably ill cancer patients. Lancet Reg Health Eur 2022; 18: 100396
    CrossrefPubMedGoogle Scholar
  • 39 Singer L, Primdahl D, Kumthekar P. Neuro-oncology in women: clinical considerations. Neurol Clin 2023; 41 (02) 331-342
    CrossrefPubMedGoogle Scholar
  • 40 Yap TA, Ashok A, Stoll J. et al. Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines. JAMA Netw Open 2022; 5 (05) e2213070
    CrossrefPubMedGoogle Scholar
  • 41 Bonm AV, Ritterbusch R, Throckmorton P, Graber JJ. Clinical imaging for diagnostic challenges in the management of gliomas: a review. J Neuroimaging 2020; 30 (02) 139-145
    CrossrefPubMedGoogle Scholar
  • 42 Papagno C, Casarotti A, Comi A, Gallucci M, Riva M, Bello L. Measuring clinical outcomes in neuro-oncology. A battery to evaluate low-grade gliomas (LGG). J Neurooncol 2012; 108 (02) 269-275
    CrossrefPubMedGoogle Scholar
  • 43 Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF. INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med 2023; Aug 17; 389 (07) 589-601
    CrossrefPubMedGoogle Scholar
  • 44 López-Pérez CA, Franco-Mojica X, Villanueva-Gaona R, Díaz-Alba A, Rodríguez-Florido MA, Navarro VG. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity. J Neurooncol 2022; 158 (03) 369-378
    CrossrefPubMedGoogle Scholar
  • 45 Stupp R, Taillibert S, Kanner A. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318 (23) 2306-2316
    CrossrefPubMedGoogle Scholar
  • 46 McAleenan A, Kelly C, Spiga F. et al. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev 2021; 3 (03) CD013316
    PubMedGoogle Scholar
  • 47 Patil N, Somasundaram E, Waite KA. et al. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. J Neurooncol 2021; 155 (03) 363-372
    CrossrefPubMedGoogle Scholar
  • 48 Lam K, Eldred BSC, Kevan B. et al. Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. Neurooncol Adv 2022; 4 (01) vdac030
    PubMedGoogle Scholar
  • 49 Herrlinger U, Tzaridis T, Mack F. et al; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393 (10172): 678-688
    CrossrefPubMedGoogle Scholar
  • 50 Alcaide-Leon P, Cluceru J, Lupo JM. et al. Centrally reduced diffusion sign for differentiation between treatment-related lesions and glioma progression: a validation study. AJNR Am J Neuroradiol 2020; 41 (11) 2049-2054
    CrossrefPubMedGoogle Scholar
  • 51 Hanna C, Lawrie TA, Rogozińska E. et al. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev 2020; 3 (03) CD013261
    PubMedGoogle Scholar
  • 52 Flanigan PM, Jahangiri A, Weinstein D. et al. Postoperative delirium in glioblastoma patients: risk factors and prognostic implications. Neurosurgery 2018; 83 (06) 1161-1172
    CrossrefPubMedGoogle Scholar
  • 53 Xie X, Bao S, Zhao H, Li L, Fu X. Efficacy and safety of bevacizumab for treating glioblastoma: a systemic review and meta-analysis of phase II and III randomized controlled trials. Cancer Invest 2023; 2: 1-13
    PubMedGoogle Scholar
  • 54 Gofton TE, Graber J, Carver A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. J Neurooncol 2012; 108 (03) 527-534
    CrossrefPubMedGoogle Scholar
  • 55 Graber JJ, Soliman H. Palliative care in neuro-oncology. Ann Palliat Med 2021; 10 (01) 836-837
    CrossrefPubMedGoogle Scholar
  • 56 Vanhauwaert D, Pinson H, Sweldens C. et al; QINO Consortium. Quality indicators in neuro-oncology: review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey. J Neurooncol 2022; 157 (02) 365-376
    CrossrefPubMedGoogle Scholar
  • 57 Lin CC, Callaghan BC, Burke JF. et al. Disputes and debates: comment on Lin et al. “Geographic variation in neurologist density and neurologic care in the United States”. Neurology 2021; 96 (03) e309-e321
    PubMedGoogle Scholar